Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mucic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL2158124 | 0.88 | TSHR (0.67) | PDE4ATSHRCYP2C9HDAC1HDAC2 | |
| Cadaverine Tartrate SCHEMBL27833573 | 0.85 | TSHR (0.62) | PDE4ATSHRCYP2C9HDAC1HDAC2 | |
| Mucic Acid SCHEMBL17594183 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 | |
| Mucic Acid SCHEMBL19695496 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 | |
| Mucic Acid SCHEMBL5496 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 | |
| Mucic Acid SCHEMBL3514596 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 | |
| Mucic Acid SCHEMBL15895451 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 | |
| Mucic Acid SCHEMBL7224759 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 | |
| Mucic Acid SCHEMBL5497 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 | |
| Mucic Acid SCHEMBL77363 | 0.84 | TSHR (0.69) | PDE4ATSHRCYP2C9TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768832-A | Preparation method of 2,5-furandicarboxylic acid compound | 江苏赛瑞克新材料科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| WO-2023169517-A1 | METHOD FOR PREPARING 2,5-FURANDICARBOXYLIC ACID COMPOUND | 江苏赛瑞克新材料科技有限公司 | 2023-09-14 | — | — | WO | claimed |
| US-20040220259-A1 | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels | YU RUEY J (US) | 2004-11-04 | — | — | US | claimed |
| WO-2004093722-A2 | TOPICAL TREATMENT OF DERMATOLOGICAL DISORDERS ASSOCIATED WITH REACTIVE OR DILATED BLOOD VESSELS | YU RUEY J (US) | 2004-11-04 | — | — | WO | claimed |
| US-20250009621-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | L'OREAL (FR) | 2025-01-09 | — | — | US | disclosed |
| WO-2025006991-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | L'OREAL (FR) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024211914-A1 | ESTERIFIED SUGAR OXIDATION PRODUCTS | SOLUGEN, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-116768832-A | Preparation method of 2,5-furandicarboxylic acid compound | 江苏赛瑞克新材料科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023169517-A1 | METHOD FOR PREPARING 2,5-FURANDICARBOXYLIC ACID COMPOUND | 江苏赛瑞克新材料科技有限公司 | 2023-09-14 | — | — | WO | disclosed |
| US-20210214298-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | UNIV CALIFORNIA (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3333152-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | The Regents of The University of California Santa Cruz (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3289000-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | The Regents of The University of California (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20040220259-A1 | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels | YU RUEY J (US) | 2004-11-04 | — | — | US | disclosed |
| EP-0831767-B1 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | YU RUEY J (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-0831767-A4 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | YU RUEY J (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0831767-A1 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | Yu, Ruey J., Dr. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5686489-A | TOPICALLY APPLIED TO INDUCE GLYCOSAMINOGLYCAN, PROTEOGLYCAN, COLLAGEN AND ELASTIN BIOSYNTHESIS; WRINKLE RESISTANCE | TRISTRATA TECHNOLOGY, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1996040047-A1 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | YU RUEY J (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0375388-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1994-03-02 | — | — | EP | disclosed |
| EP-0375388-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009621-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | EBP, ADH1A, ADH1C | SLC6A3 1191/4885PDE4A 1325/4885TSHR 3405/4885 |
| US-20040220259-A1 | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels | AKR1C3, ALDOA, AKR1C2 | SLC6A3 2693/4885PDE4A 2135/4885TSHR 4727/4885 |
| US-20210214298-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | GCK, G6PD, SLC2A4 | SLC6A3 309/4885PDE4A 1820/4885TSHR 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.